A Daily Network publication
Explore the network
Private Wealth Daily
Independent Intelligence on the Private Wealth Industry
Friday, October 2, 2026The Morning Brief →Sign in
BBHVanEckINDEX

VanEck Biotech ETF

$238.74-2.39% vs prior close
17224652-WK

Price through Oct 1 · Flows through Sep 30. Figures use the latest available records, not a live quote. Fund details retrieved Oct 1. Holdings snapshot retrieved Oct 1.

The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Price & daily flows
229.8208.9187.9238.74DAILY NET FLOWOct 1Jan 30Jun 1Oct 1

SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 3Y SHOWN · NET −$145M OVER THIS RANGE

The desk’s read

Money keeps arriving — +$3M of net inflows over the past month, about 0.5% of the fund's asset base, while the price has returned +26.1% so far this year. At 0.35% a year it is not the cheapest way in — AVIE has a reported fee of 0.25%.

COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH

$488Massets under management
0.35%expense ratio · $35 per $10,000 a year
+$3Mnet flow, trailing month
12Kavg daily volume, 30 days
26holdings · US-domiciled
1999listed November 23, 1999 · beta 0.63
The book at a glance
AMGN-3.4%GILD-1.0%VRTX-3.1%REGN-3.1%MRNA-1.9%NTRA-1.2%ARGX-2.4%IQV-3.0%RVMD+0.3%ILMN-2.9%GH-2.0%ONC-2.0%BIIB-1.4%ALNY-6.3%UTHR+5.4%INCY-3.5%INSM-4.9%BNTX-1.5%CRL-2.8%NBIX-0.8%ICLR-4.8%TECH-0.1%BMRN-2.6%TEM-6.6%QGEN-3.9%

CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS

HoldingsDownload CSV
#HoldingWeightPriceDay52-wk
1AMGNAMGEN15.79%$407.27-3.4%
2GILDGILEAD SCIENCES13.19%$147.50-1.0%
3VRTXVERTEX PHARMACEUTICALS8.22%$506.74-3.1%
4REGNREGENERON PHARMACEUTICALS6.50%$734.81-3.1%
5MRNAMODERNA6.07%$188.94-1.9%
6NTRANATERA5.34%$408.47-1.2%
7ARGXARGENX SE4.59%$936.00-2.4%
8IQVIQVIA HOLDINGS4.47%$260.72-3.0%
9RVMDREVOLUTION MEDICINES4.22%$205.89+0.3%
10ILMNILLUMINA4.05%$265.72-2.9%
11GHGUARDANT HEALTH3.01%$174.75-2.0%
12ONCBeiGene2.76%$358.77-2.0%
13BIIBBIOGEN2.73%$222.82-1.4%
14ALNYALNYLAM PHARMACEUTICALS2.70%$231.18-6.3%
15UTHRUNITED THERAPEUTICS2.24%$571.38+5.4%

The full book, free with one sign-in.

Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.

Sign in to see all 26
Sector weights
Healthcare100%
Health Technology86.57%
Commercial Services7.67%
Health Services5.76%
PORTFOLIO COMPOSITION, LATEST DISCLOSURE
Country weights
United States93.37%
Ireland4.43%
China3.87%
Netherlands2.82%
Germany1.95%
Spain1.67%
Hong Kong1.62%
Switzerland0.81%
PORTFOLIO COMPOSITION, LATEST DISCLOSURE
Performance
1 week-2.7%
1 month-0.3%
3 months+16.8%
6 months+30.5%
YTD+26.1%
1 year+38.7%
3 years—

PRICE RETURN, DISTRIBUTIONS NOT REINVESTED

Net flows
1 week−$2M
1 month+$3M
3 months+$12M
YTD+$5M
1 year−$23M

CREATION/REDEMPTION DOLLARS, DAILY RECORDS

Monthly net flows
OctNovDecJanFebMarAprMayJunJulAugSep
DAILY CREATION/REDEMPTION RECORDS, TRAILING TWELVE MONTHS
The risk read
23%realized volatility, 30 days (annualized)
21%realized volatility, 1 year
-10.5%deepest fall from a peak, 1 year
-2.8%latest close versus that peak

The top holding is 15.8% of the book; the top ten carry 72%. Spread across 25+ names, it behaves like roughly 14 equally-weighted positions.

VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK

Options tape
6calls · latest snapshot
1puts · latest snapshot
0.17put/call ratio
13Kshares traded
Most-traded holdings, options premiumBullishBearish
MRNA MODERNA$35M$34M
TEM TEMPUS AI INC$4M$5M
NTRA NATERA$3M$6M
AMGN AMGEN$3M$4M
UTHR UNITED THERAPEUTICS$2M$2M

TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES

The case against BBH

Due diligence cuts both ways. These funds sit on the same shelf and beat BBH on at least one dimension that matters — the fee, the asset base, or where the money is going.

FundFeeAssetsFlow, 1MThe case
SPDW State Street SPDR Portfolio Developed World ex-US ETF0.03%$41.5B+$286M-32bp on fee · 85× the assets · +$286M in over the monthHead-to-head
SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF0.03%$18.2B+$199M-32bp on fee · 37× the assets · +$199M in over the monthHead-to-head
IDEV iShares Core MSCI International Developed Markets ETF0.04%$32.9B+$497M-31bp on fee · 67× the assets · +$497M in over the monthHead-to-head
IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF0.04%$23.7B+$575M-31bp on fee · 48× the assets · +$575M in over the monthHead-to-head
IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF0.04%$18.6B+$412M-31bp on fee · 38× the assets · +$412M in over the monthHead-to-head
Sign in to save this to The RecordA timestamped copy for the file — documentation, not advice.
InstrumentsHarvest substitutesTrade cost at $1MClient tearsheetStress this fund
Every weekday · 6:30 a.m. ET

The Morning Brief

The private wealth industry in four minutes, every weekday at 6:30 a.m. ET. Free.